Meeting
2019 ASCO Annual Meeting
A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial.
Authors
Deborah Kay Armstrong
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD
Deborah Kay Armstrong , Kathleen N. Moore , Austin Miller , Katherine M. Bell-McGuinn , Russell J. Schilder , Paula M. Fracasso , Joan L. Walker , Linda R. Duska , Cara Amanda Mathews , Alice P. Chen , David M. O'Malley , Heidi J. Gray , Roisin Eilish O'Cearbhaill , Saketh R Guntupalli , Andrea R. Hagemann , Carol Aghajanian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT00989651
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5523)
DOI
10.1200/JCO.2019.37.15_suppl.5523
Abstract #
5523
Poster Bd #
346
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial.
First Author: George Somlo
Poster
2021 ASCO Annual Meeting
Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.
First Author: Judith Michels
Poster
2017 ASCO Annual Meeting
A phase I dose-escalation study of intraperitoneal (IP) cisplatin, IV/IP paclitaxel, IV bevacizumab, and oral olaparib for newly diagnosed adenxal carcinoma.
First Author: Jason A. Konner
Poster
2016 Gastrointestinal Cancers Symposium
Phase I study of veliparib with gemcitabine and radiation therapy in patients with borderline resectable and locally advanced unresectable pancreatic cancer.
First Author: Richard Tuli